mivacurium (mivacron) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Mivacurium chloride (Mivacron) is a new benzylisoquinolinium choline-like diester neuromuscular blocking drug with an onset of action at equipotent doses that is comparable to atracurium and vecuronium but slower than succinylcholine. MIVACRON (a mixture of three stereoisomers) binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine. MIVACRON is a short-acting neuromuscular blocking agent indicated for inpatients and outpatients, as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.   NCATS

Chemistry

  • SMILES: COc1cc2CC[N+](C)(CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]3(C)CCc4cc(OC)c(OC)cc4[C@H]3Cc5cc(OC)c(OC)c(OC)c5)[C@H](Cc6cc(OC)c(OC)c(OC)c6)c2cc1OC
  • InChIKey: ILVYCEVXHALBSC-OTBYEXOQSA-N
  • Mol. Mass: 1029.28
  • ALogP: Missing data
  • ChEMBL Molecules:
    mivacurium  
    mivacurium chloride  
More Chemistry

Pharmacology

Alternative names

bw b1090u | bw-b1090u | bw-b 1090u | bw-b-1090u | bwb109ou | bw-b109ou | bw-b109ou dichloride | mivacron | mivacurium | mivacurium chloride

Organizations (15)

Research & Development (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (1)


 

Musculoskeletal Manipulations (approved 1992)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Infant, Newborn (Phase 4)

Infant, Premature (Phase 4)

Intubation (Phase 4)

Kidney Diseases (Phase 4)

Liver Diseases (Phase 2)

Muscle Relaxation (Phase 1)

Pharmacological and Toxicological Phenomena (Phase 4)

Sex (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial Organizations: 10

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue